Churchill Capital Corp XI Class A Ordinary Shares (CCXI)vsMarblegate Acquisition Corp (GATE)
CCXI
Churchill Capital Corp XI Class A Ordinary Shares
$10.22
0.00%
FINANCIAL SERVICES · Cap: $3.74B
GATE
Marblegate Acquisition Corp
$36.05
0.00%
FINANCIAL SERVICES · Cap: $417.54M
Smart Verdict
WallStSmart Research — data-driven comparison
GATE leads profitability with a 0.0% profit margin vs 0.0%. GATE earns a higher WallStSmart Score of 32/100 (F).
CCXI
Avoid32
out of 100
Grade: F
GATE
Avoid32
out of 100
Grade: F
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 549.0% year-over-year
No standout strengths identified
Areas to Watch
0.0% earnings growth
0.0% margin — thin
ROE of -47.0% — below average capital efficiency
Negative free cash flow — burning cash
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
ROE of 0.0% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : CCXI
The strongest argument for CCXI centers on Revenue Growth. Revenue growth of 549.0% demonstrates continued momentum.
Bull Case : GATE
GATE has a balanced fundamental profile.
Bear Case : CCXI
The primary concerns for CCXI are EPS Growth, Profit Margin, Return on Equity.
Bear Case : GATE
The primary concerns for GATE are Revenue Growth, EPS Growth, Market Cap.
Key Dynamics to Monitor
CCXI profiles as a hypergrowth stock while GATE is a value play — different risk/reward profiles.
CCXI carries more volatility with a beta of 1.23 — expect wider price swings.
CCXI is growing revenue faster at 549.0% — sustainability is the question.
GATE generates stronger free cash flow (-340,169), providing more financial flexibility.
Bottom Line
CCXI scores higher overall (32/100 vs 32/100) and 549.0% revenue growth. Both earn "Avoid" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Churchill Capital Corp XI Class A Ordinary Shares
FINANCIAL SERVICES · SHELL COMPANIES · USA
ChemoCentryx, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of new drugs for inflammatory disorders, autoimmune diseases, and cancer in the United States. The company is headquartered in Mountain View, California.
Marblegate Acquisition Corp
FINANCIAL SERVICES · SHELL COMPANIES · USA
Marblegate Acquisition Corp. The company is headquartered in New York, New York.
Compare with Other SHELL COMPANIES Stocks
Want to dig deeper into these stocks?